PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1462708
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1462708
According to Stratistics MRC, the Global Loop-mediated Isothermal Amplification Market is accounted for $103.5 million in 2023 and is expected to reach $165.1 million by 2030 growing at a CAGR of 6.9% during the forecast period. Loop-mediated isothermal amplification (LAMP) is a nucleic acid amplification technique used to rapidly replicate DNA under constant temperature conditions. It employs four to six primers targeting multiple regions of the DNA, including loop structures, which initiate strand displacement and amplification. LAMP reactions typically occur between 60-65°C, eliminating the need for thermal cycling equipment. By producing large amounts of DNA within 30-60 minutes, LAMP enables rapid detection of target sequences, such as pathogens or genetic variations. Its simplicity, speed, and high specificity make it valuable in various fields, including clinical diagnostics, environmental monitoring, and food safety testing.
Rising demand for rapid and accurate diagnostics
The increasing need for quick and precise diagnostics has propelled the growth of the LAMP market. Healthcare providers are adopting loop-mediated isothermal amplification technology to meet the demand for rapid testing, especially in scenarios where timely diagnosis is critical, such as infectious disease outbreaks or emergency situations. Companies are investing in research and development to improve the sensitivity, specificity, and multiplexing capabilities of loop-mediated isothermal amplification assays. This has led to the development of advanced loop-mediated isothermal amplification-based diagnostic platforms and reagents boosting the growth of the market.
Limited multiplexing capability
Limited multiplexing capability means that each target must be detected in a separate reaction, increasing the time, cost, and resources required for diagnostics. This reduced efficiency and cost-effectiveness can deter healthcare providers from adopting loop-mediated isothermal amplification technology, especially in settings where high throughput and resource efficiency are crucial. Thus the limited multiplexing capability of loop-mediated isothermal amplification technology can put it at a competitive disadvantage in the market, as healthcare providers may opt for alternative technologies that better meet their multiplexing needs hamper the market growth.
Increasing prevalence of chronic diseases
Chronic diseases often require regular monitoring and early detection for effective management and treatment. The need for rapid and accurate diagnostic solutions to detect these diseases at an early stage has increased. LAMP technology, with its rapid turnaround time and high sensitivity, is well-suited for diagnosing chronic conditions, enabling timely intervention and improved patient outcomes. Furthermore governments and healthcare organizations worldwide are implementing screening programs to detect chronic diseases early, thereby reducing disease burden and healthcare costs.
Limited infrastructure in resource-limited settings
Resource-limited settings often lack adequate healthcare infrastructure, including laboratory facilities, trained personnel, and reliable electricity supply. The requirement for specialized equipment and trained personnel to conduct loop-mediated isothermal amplification assays may pose accessibility challenges in such settings, limiting the adoption of this technology. Additionally, the need for uninterrupted power supply and climate-controlled storage conditions for reagents further adds to the cost burden, making LAMP technology less feasible in these environments.
Covid-19 Impact
The COVID-19 pandemic has accelerated the adoption of Loop-mediated Isothermal Amplification (LAMP) technology for rapid and decentralized testing. LAMP's simplicity, speed, and accuracy have made it a valuable tool for COVID-19 diagnostics, especially in resource-limited settings and point-of-care environments. The demand for LAMP-based assays and platforms has surged as healthcare systems seek efficient testing solutions to curb the spread of the virus. However, supply chain disruptions, regulatory challenges, and competition from other diagnostic technologies have also influenced the LAMP market dynamics during the pandemic. Overall, COVID-19 has both propelled and challenged the growth of the LAMP market.
The DNA (deoxyribonucleic acid) segment is expected to be the largest during the forecast period
The DNA (deoxyribonucleic acid) segment is estimated to have a lucrative growth, as it is designed to amplify DNA sequences. It is widely used in molecular biology research, clinical diagnostics, and various other fields where rapid and sensitive detection of DNA is required. Moreover in clinical diagnostics, the presence or absence of specific DNA sequences is often indicative of disease states, genetic mutations, or pathogen infections. Loop-mediated isothermal amplification assays are designed to detect these DNA targets with high sensitivity and specificity. Therefore, the availability of loop-mediated isothermal amplification assays that can accurately amplify and detect target DNA sequences influences the adoption and growth of the LAMP market in diagnostic applications.
The reverse transcription LAMP segment is expected to have the highest CAGR during the forecast period
The reverse transcription LAMP segment is anticipated to witness the highest CAGR growth during the forecast period, as it allows for the amplification of RNA targets, in addition to DNA, which significantly broadens the application spectrum of LAMP technology. This expansion enables the detection of RNA viruses, RNA-based biomarkers, and RNA transcripts, opening up new opportunities in infectious disease diagnosis, gene expression analysis, and RNA research. Furthermore this capability is useful in gene expression profiling studies, biomarker discovery, and monitoring cellular responses to stimuli or treatments thus all the above factors drive the market growth.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the prevalence of infectious diseases in the Asia Pacific region, including tuberculosis, dengue, malaria, and emerging infectious diseases like COVID-19, is driving the demand for rapid diagnostic solutions. Its ability to provide quick and accurate results is particularly valuable in controlling disease outbreaks and managing public health challenges. Additionally the presence of a robust biotechnology and life sciences industry in countries like Japan, South Korea, China, and India fosters research and development activities in loop-mediated isothermal amplification technology propel the growth of the market.
North America is projected to have the highest CAGR over the forecast period, despite high healthcare standards; North America still faces challenges related to infectious diseases such as influenza, Lyme disease, and sexually transmitted infections. LAMP technology's rapid and accurate diagnostic capabilities make it attractive for healthcare providers in the region. The demand for decentralized testing solutions is increasing in North America, especially in remote or underserved areas and during public health emergencies encourage the growth of the market.
Key players in the market
Some of the key players in the Loop-mediated Isothermal Amplification Market include Bio-Rad Laboratories, Inc., CapitalBio, Deaou Biotechnology, Eiken Chemical , Excellgen Inc, GENESIS Dhelix, HiberGene Diagnostics, Jena Bioscience GmbH, Mast Group Ltd., Merck KGaA, Meridian Bioscience, Inc., New England Biolabs, NIPPON GENE CO., LTD, OptiGene, QIAGEN N.V, Singuway and Thermo Fisher Scientific
In March 2024, Thermo Fisher Scientific Launches CorEvitas Clinical Registry in Generalized Pustular Psoriasis. This registry, which is open to enrollment, is CorEvitas' 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.
In January 2024, Nippon Gene Co., Ltd. announced the National Agriculture and Food Research Organization (NARO) have developed two molecular-based diagnostic kits for Johne's disease.
In July 2023, Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement. The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.